Monika Richter focuses her practice on the biotechnology and pharmaceuticals sector. She advises national and international clients on various legal matters related to the development and partnering of pharmaceutical compounds and products, with a particular focus on strategic alliances, license agreements, research collaborations and co-development agreements. Her work likewise includes financing and corporate transactions as well as mergers and acquisitions.

Show More


  • Advised REGENXBIO on co-development and licensing partnership with AbbVie for development of RGX-314, a potential one-time gene therapy for retinal diseases
  • Advised STADA on exclusive licensing transaction with Calliditas for commercialization of novel specialty drug for treatment of chronic autoimmune kidney disease
  • Advised Merck on out-licensing transaction with Diaccurate for development of clinical stage cancer therapy candidate and on various other collaboration agreements

Show More


  • Legal 500 EMEA 2022: “Monika Richter: Forward-looking, prudent, razor-sharp when it comes to implementing client interests.”; „The team around Monika Richter and Deniz Tschammler offers an exceptional combination of industry expertise in the healthcare sector and deal experience.
  • Handelsblatt/Best Lawyers 2022 Germany: Leading Lawyer for Biotechnology Law and Life Sciences Practice
  • Handelsblatt/Best Lawyers 2021 Germany: Leading Lawyer for Biotechnology Law and Life Sciences Practice
  • Leaders League’ 2019 Guide, Innovation, Technology & Patents: “Excellent” in the Health, pharma & biotechnology category


Humboldt University of Berlin, Dr. jur. (PhD), 2008
Court of Appeal, Berlin, Second State Exam, 2004
Universities of Tübingen and Heidelberg, First State Exam, 2002


Show More